Cathie's Ark Logo
CRISPR Therapeutics AG Logo

ARKG Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

TherapeuticsGene TherapyCAR-T Cell TherapyCRSPR Gene Editing
Date
Direction
Shares
Fund Weight
Fund
April 12, 2023
BUY13.764k0.0318%ARKG
April 11, 2023
BUY979.0000.0023%ARKG
April 10, 2023
BUY7.785k0.0182%ARKG
April 5, 2023
BUY1.568k0.0035%ARKG
December 29, 2022
BUY8.134k0.018%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
4.76%$5.09b
🏋🏿‍♂️Weight Rank In ARKG🌏Country
5🇨🇭Switzerland
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
11$70.01
🎫ARK Ownership Percent
1.93%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Website
www.crisprtx.com

Other ETFs That Hold CRSP

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.7%
GNOMGlobal X Genomics & Biotechnology ETF3.52%
ARKKARK Innovation ETF3.37%
XBISPDR® S&P Biotech ETF1.01%
IBBiShares Biotechnology ETF0.35%
LABUS&P Biotech Bull 3X Shares ETF0.242%

Research Notes and Commentary for CRSP

No Research Notes Found for CRSP